Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 27, 2016. The report announces a significant regulatory milestone: the European Commission granted marketing authorisation for Strimvelis, the world's first ex-vivo stem cell gene therapy approved for treating ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). The therapy is a collaborative effort between GSK, Fondazione Telethon, and Ospedale San Raffaele.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on the regulatory approval and clinical data of a specific product.
Material Changes and Clinical Data
The primary material change is the regulatory approval of Strimvelis in the European Union. Key clinical data supporting this approval includes:
- Survival Rates: A 100% survival rate at three years post-treatment was observed in the pivotal study (n=12). All 18 children who contributed data to the marketing authorisation are alive today.
- Intervention-Free Survival: 92% of the pivotal study population did not require enzyme replacement therapy or stem cell transplantation for over three months post-treatment. In the broader evaluable population (n=17), intervention-free survival was 82%.
- Follow-up: The median follow-up duration for the 18 patients is approximately seven years, with the first patient treated over 13 years ago.
- Market Size: ADA-SCID affects an estimated 15 children per year in Europe.
Outlook, Risks, and Management Commentary
Management Commentary: GSK leadership described the approval as the start of a "new chapter" in treating rare genetic diseases. The therapy is indicated for patients with ADA-SCID who lack a suitable HLA-matched related stem cell donor. Treatment is administered at Ospedale San Raffaele in Milan.
Risks and Safety:
- Adverse Events: Adverse events were reported for all 18 patients, primarily usual childhood infections (upper respiratory tract infection, gastroenteritis, rhinitis).
- Serious Adverse Events (SAEs): Of 39 SAEs reported post-treatment, 62% were infections, most commonly device-related (e.g., central venous catheter infections).
- Long-term Effects: Some patients experienced neurologic, CNS, or hearing impairments continuing post-treatment. No leukaemic events have been observed to date.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks outlined in their 2015 Form 20-F.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Strimvelis in the EU.
- Confirm the capacity and operational readiness of Ospedale San Raffaele to administer the therapy.
- Review the long-term safety monitoring plan, specifically regarding neurologic and hearing impairments.
- Assess the potential for regulatory approval in other major markets (e.g., US FDA) beyond the EU.
- Examine the financial terms of the collaboration between GSK, Telethon, and Ospedale San Raffaele regarding revenue sharing.